PHARM: Ovarian and Bladder Cancer Flashcards

1
Q

What protein is usually elevated in most ovarian cancer cells and change in blood level is a marker for drug efficacy or tumor proliferation?

A

CA-125

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the most common type of bladder cancer?

A

superficial transitional cell carcinomas

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

How do superficial transitional cell carcinomas present?

A

hematuria (leads to an early presentation)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What cells become cancerous in transitional cell carcinomas? Why?

A

transformation of the cells lining the urothelial surface; these are cells that remain in contact with high concentrations of chemicals

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Where is stage Ta bladder cancer located?

A

confined to epithelium (mucosa)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Where is stage T1 bladder cancer located?

A

invades sub-epithelial CT (lamina propria)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Where is stage T2a/T2b bladder cancer located?

A

invades superficial/deep muscle

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Where is stage T3a/T3b bladder cancer?

A

microscopically/macroscopically invading perivesicle fat

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Where is stage T4a/T4b bladder cancer located?

A

tumor invades surrounding organs/pelvis or abdominal wall

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the treatment for locally confined ovarian cancer?

A

intra-peritoneal instillation of cisplatin provides for juxtaposition of high concentrations of chemotherapeutic in direct contact with the spreading cancer cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

How does intra-peritoneal chemotherapy work?

A
  • Patients receive a 1-2L instilled volume that is retained for up to 2 hr, then drained off.
  • During this time supine patients rotate from side-to-side to ensure adequate coverage of peritoneal surfaces.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

You do you treat “superficial” bladder cancer?

A

treated by trans-urethral resection of the bladder cancer (TURBC) + intravesical instillation of a high concentration of chemotherapeutic (ex. mitomycin or BCG for >1 yr) to eradicate any transformed cells that remain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

How do you treat bladder cancer that has “progressed”?

A

chemo-radiation or conventional systemic chemotherapy are employed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the last line therapy for bladder cancer?

A

total cystectomy and subsequent lifestyle changes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is a big risk of TURBC?

A

if you penetrate too deep in the bladder tissue, you may compromise retention of drug in the bladder lumen and significantly increase the potential for drug systematization

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Why might women with late stage ovarian cancer elect to get intra-peritoneal chemotherapy?

A

troublesome ascites may lead them to elect intraperitoneal drug instillations in a palliative mode to decrease the rate of build up of the ascites.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What is the chemo combination for stage 1-2 ovarian cancer?

A

carboplatin- or cisplatin-based regimen usually including cyclophosphamide and/or doxorubicin

18
Q

What is the chemo conbination for stages 3-4 ovarian cancer?

A

carboplatin or cisplatin with paclitaxel

19
Q

MOA: Forms DNA intrastrand crosslinks and adducts

A

Cisplatin and carboplatin

20
Q

MOA: Pro-drug of active alkylating moiety

A

Cyclophosphamide

21
Q

MOA: Intercalator, free radical generator, topo II inhibitor

A

Doxorubicin

22
Q

MOA: Microtubule stabilizer inhibiting depolymerization

A

Paclitaxel

23
Q

TOXICITY: Allergic reactions; dose related myelosuppression, cumulative anemia; dose-related N/V.

A

carboplatin

24
Q

TOXICITY: Allergic reactions; dose related severe nephrotoxicity, myelosuppression and N/V. Significant ototoxicity (tinnitus and deafness) reported in children

A

Cisplatin

25
Q

TOXICITY: Blood dyscrasias→ anemia and infection; renal compromise; hemorrhagic cystitis; N/V, rashes; amenorrhea/infertility; pulmonary fibrosis

A

Cyclophosphamide

26
Q

TOXICITY: Myelosuppression, CHF, hepatic disease, secondary malignancies, extravasational necrosis; N/V

A

Doxorubicin

27
Q

TOXICITY: hypersensitivity; myelosuppression; myalgia and arthralgia

A

paclitaxel

28
Q

Which of the ovarian cancer drugs leads to blood chemistry dyscrasia (elevated hepatic enzymes, BUN, and creatinine)?

A

carboplatin

29
Q

With which ovarian cancer drug must you monitor the patient for secondary malignancies?

A

cyclophosphamide

30
Q

What are the drugs used to treat bladder cancer?

A
Bacillus Calmette-Guerin (BCG)
Cisplatin
Doxorubicin
MItomycin C
Thiotepa
31
Q

How is BCG administered?

A

(instilled and held 1-2 hours, 6X/week)

32
Q

MOA: Polyfunctional alkylator with loss of aziridine (alkylator) moiety. The remaining moiety, diethylenethiophosphoramide forms DNA interstrand cross-links.

A

Thiotepa

33
Q

MOA: Mono- and bi-functional alkylating agent

A

Mitomycin C

34
Q

MOA: Intercalator, free radical generator, topo II inhibitor

A

Doxorubicin

35
Q

MOA: Forms DNA intrastrand crosslinks and adducts (bladder cancer drug)

A

cisplatin

36
Q

MOA: Binds to urothelial cells, attracts APCs and ultimately leads to the production of a host of immune system effector cells, such as cytotoxic T-Lymphocytes (CTLs) and Natural Killer (NK) cells.

A

Bacillus Calmette-Guerin

37
Q

What bladder cancer drug has an effect that lasts days to months? (potential for “boosters”)

A

Bacillus Calmette-Guerin

38
Q

TOXICITY: Pancytopenia (IV); when used IVe leads to chemical cystitis, contact dermatitis (palmar and plantar erythemas if contact made with instillate solution or void volume)

A

Mitomycin C

39
Q

TOXICITY: Pancytopenia (IV); when used IVe you expect dysuria, urinary retention, chemical/hemorrhagic cystitis; renal dysfunction

A

Thiotepa

40
Q

TOXICITY: pulmonary infiltrates (dyspnea and unproductive cough)

A

Mitomycin C

41
Q

Which bladder cancer drug is a lipophillic, small molecular weight drug that can easily penetrate urotehilal tissue?

A

thiotepa